News 2023-03-25
Porton Released 2022 CSR Report
Porton Pharma Solutions Ltd. recently released 2022 CSR Report which is its seventh CSR report since IPO. This report demonstrates the company's ideas and achievements in fulfilling social responsibility from aspects such as "improving corporate governance", "providing high-quality services", "empowering employee development", "practicing green development", and "participating in community co-development".
Portonisalways committed to sustainable development，adopting a development model that balances economic benefits with gover-nance, environment,and social welfare, in order tocontinuously enhance the company'sriskresistanceandsustainable business capabilities.
Currency:RMB
Others
More
News 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
